Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PCI-24781 · 3 trials · 9 indications
frequency, severity and relatedness of adverse events
Number of patients experienced DLT in each cohort
| Arm | Type | Description |
|---|---|---|
| PCI-24781 | EXPERIMENTAL | - |
| 1 | EXPERIMENTAL | - |
| Arm 1 | EXPERIMENTAL | All study subjects will receive PCI-24781 (study drug). |
| Name | Type | Description |
|---|---|---|
| PCI-24781 | DRUG | Subjects enrolled in this study will receive PCI-24781 administered orally at the schedule and dosage from their prior protocol. |
Inclusion Criteria: 1. Men and women with cancer that did not progress while treated with PCI 24781 PO for at least 6 months and who want to continue receiving study drug 2. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 3. Agreement to use contraception during the study and fo...
Top 20 of 66 competitors
PCI-24781 is an investigational small molecule being studied for the treatment of lymphoma and other neoplasms by site. It has been evaluated in patients with non-Hodgkin lymphoma, Hodgkin disease, multiple myeloma, and chronic lymphocytic leukemia. The drug is in Phase 1 clinical development and is not yet approved.
PCI-24781 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV. The company is conducting clinical trials of this investigational oncology drug in the United States.
PCI-24781 is in Phase 1 clinical development. Three Phase 1 trials have been completed, with a total enrollment of 62 patients. The drug remains investigational and has not received regulatory approval for any indication.
PCI-24781 has been studied in three completed Phase 1 trials: NCT00562224, NCT00724984, and NCT01149668. These trials assessed the safety and tolerability of the drug in patients with advanced cancer, lymphoma, and other hematologic malignancies. All trials were conducted in the United States.
PCI-24781 is administered as an oral capsule. The clinical trials evaluated the safety and tolerability of this oral formulation in adult patients with cancer, including those with lymphoma and related conditions.
PCI-24781 is also known as abexinostat. It is a small molecule oncology drug being developed by AbbVie Inc. for the treatment of lymphoma and other cancers. The drug is currently in Phase 1 clinical development.